ALP Bio AG, a Swiss biotech developing an immune organoid and AI platform for immunogenicity intelligence, today announced the closing of a CHF 1.75 million pre-seed financing round. The round was led by Munich-based venture capital firm 42CAP, with participation from Venture Kick and a group of strategic angel investors.

The funding will accelerate ALP Bio's platform, which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.

Tackling one of the costliest hidden risks in biologics
Immunogenicity, including anti-drug antibody (ADA) responses, remains one of the most difficult risks in biologics development. These immune responses can reduce therapeutic efficacy, raise safety concerns, and force teams to abandon or rework programs late in development. Today, most immunogenicity signals only emerge in clinical trials, when the cost of course correction is highest.

A hybrid platform combining wet-lab biology and AI
ALP Bio is building a hybrid platform that brings more clinically relevant signal into earlier antibody decision-making. The company combines experimentally measured human immune organoid readouts with machine learning models that support risk assessment and antibody redesign. The platform builds on human tonsil organoid technology, which models relevant immune activity in vitro, and AI models designed to learn from increasingly rich biological datasets. ALP Bio is developing the platform to support lead candidate screening, ADA risk stratification, and sequence optimization while preserving therapeutic function.

"Immunogenicity is one of the largest hidden costs in biologics, and the industry has accepted late-stage surprises as the norm for too long," said Dr. Christian Vahlensieck, CEO of ALP Bio AG. "This financing lets us scale the experimental and computational foundation of our platform and partner with teams who want to make antibody development more predictable from the start."

"ALP Bio is doing for biologics what high-throughput screening did for small molecules: collapsing a years-long bottleneck into a tractable design loop," said Thomas Wilke, Partner at 42CAP. "The team's combination of immune organoid biology and sequence-level AI is the most credible attempt we have seen to address immunogenicity at the source."

Use of funds
The pre-seed round will be used to expand ALP Bio's experimental immune organoid capabilities, increase automation and throughput, launch early partner projects focused on immunogenicity risk in antibody lead candidates, and build out scientific and commercial capacity in Switzerland and the US.

ALP Bio is now engaging pharmaceutical and biotechnology partners interested in early-access collaborations on immunogenicity. The company will be present at Swiss Biotech Days 2026 in Basel from 5 to 6 May.